Bio­gen spin­off be­gins trad­ing to­day; New on­col­o­gy chief at As­traZeneca

• Shares of Bio­gen’s he­mo­phil­ia spin­off Biover­a­tiv be­gan trad­ing to­day on a “when is­sued” ba­sis and will be­gin reg­u­lar trad­ing on Feb­ru­ary 2nd un­der the BIVV sym­bol. The com­pa­ny gets start­ed with about 400 staffers un­der CEO John Cox at a time a num­ber of gene ther­a­pies in the clin­ic look to dis­rupt the field.

• Jamie Freed­man is tak­ing over as the new head of on­col­o­gy at As­traZeneca af­ter Mond­her Mahjoubi left to join In­nate. Freed­man is com­ing in from the phar­ma gi­ant’s Med­Im­mune sub­sidiary. Ear­li­er he had worked at GSK and OP­KO Health, re­ports PM­Live.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.